Cloverleafbio
Founded 2023 · 4 employees on LinkedIn · 1 known investors
Find your way into Cloverleafbio
1,052 people in our graph share verified history with the Cloverleafbio team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Austin Draycott · together at Stanford University (overlapped)
×5knows the team · via Stanford University
×2knows the team · via Brown University
×2knows the team · via Massachusetts Institute of Technology
knows the team · via Yale University
knows the team · via Saint Ann's School
Cloverleaf Bio is developing engineered tRNA therapeutics for oncology, designed to inhibit multiple enzymes required for cancer growth from a single molecule. The company focuses on cancer treatment within the biotech and therapeutics space.
Founders & leadership
Cloverleafbio was founded in 2023 by Austin Draycott, Wendy Gilbert, and Cole Lewis.
AD
Austin DraycottinCo-FounderAustin Draycott completed a PhD in biochemistry at Yale University under Wendy Gilbert, where he developed methods to study epitranscriptomic modifications and their role in lung cancer. He is co-founder and CEO of Cloverleaf Bio, which develops engineered tRNA therapeutics for oncology.
WG
Wendy GilbertCo-Founder
CL
Cole LewisinCo-Founder & CSO
Investors · 1
Frequently asked questions
- What does Cloverleafbio do?
- Cloverleaf Bio is developing engineered tRNA therapeutics for oncology, designed to inhibit multiple enzymes required for cancer growth from a single molecule. The company focuses on cancer treatment within the biotech and therapeutics space.
- Who founded Cloverleafbio?
- Cloverleafbio was founded by Austin Draycott, Wendy Gilbert, Cole Lewis in 2023.
- Who are Cloverleafbio's investors?
- Cloverleafbio's investors include Draper Associates.